Latest News-Jiangsu Alphamab Biopharmaceuticals Co.,Ltd Mediaroom_Page

Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024

SUZHOU, China, Nov. 11, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2024-11-11 10:04 1354

IND Application for a Phase Ⅲ Clinical Study of KN026 Combined with Albumin-bound Docetaxel as Neoadjuvant Treatment for Breast Cancer was Approved

SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) and CSPC Pharm...

2024-10-17 10:15 1716

Alphamab Oncology and CSPC Achieved a Licensing Agreement on Anti-HER2 Bispecific ADC JSKN003 in Mainland China

SUZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced tha...

2024-09-30 10:35 3235

Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024

SUZHOU, China, Sept. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...

2024-09-16 13:03 1958

Alphamab Oncology Reports 2024 Interim Results and Business Highlights

SUZHOU, China, Aug. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported inter...

2024-08-16 11:18 3338

Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024

SUZHOU, China, Aug. 12, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2024-08-12 10:18 1837

Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products

SUZHOU, China, June 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that ...

2024-06-06 10:21 2114

Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting

* Results from the phase I part of JSKN003-102 was reported at this ASCO Annual Meeting. * JSKN...

2024-06-03 10:17 1756

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of HER3/TROP2 Bispecific ADC Drug JSKN016

SUZHOU, China, May 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that ...

2024-05-22 09:16 2046

Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting

SUZHOU, China, May 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that d...

2024-05-06 10:25 2443

Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR

* The dose-escalation results of JSKN003 was reported at this AACR conference. * JSKN003 exhibite...

2024-04-10 08:40 2052

Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights

SUZHOU, China, March 29, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported fina...

2024-03-29 10:42 8282

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033

SUZHOU, China, March 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...

2024-03-26 09:57 1446

The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine

SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...

2024-03-22 18:42 2821

Alphamab Oncology to Present Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors at AACR 2024

SUZHOU, China, March 14, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...

2024-03-14 08:39 2029

The Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications

SUZHOU, China, Feb. 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that ...

2024-02-07 09:50 1904

The Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications

Alphamab Oncology updated data from two studies of KN026 in combination with docetaxel for HER2-positive breast cancer at ESMO

* KN026 combined with docetaxel has significant efficacy in the first-line treatment of HER2-posi...

2023-10-24 08:41 3244

Latest News